News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
779,594 Results
Type
Article (64381)
Company Profile (685)
Press Release (714528)
Section
Business (220942)
Career Advice (2927)
Deals (37663)
Drug Delivery (117)
Drug Development (86701)
Employer Resources (181)
FDA (17398)
Job Trends (16571)
News (373916)
Policy (36151)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (19)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (8)
2024 Genetown Digital (10)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (13)
2025 Lone Star Bio Digital (16)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2941)
Academic (1)
Accelerated approval (5)
Adcomms (24)
Allergies (87)
Alliances (53663)
ALS (91)
Alzheimer's disease (1453)
Antibody-drug conjugate (ADC) (130)
Approvals (17380)
Artificial intelligence (258)
Autoimmune disease (19)
Automation (14)
Bankruptcy (381)
Best Places to Work (12586)
BIOSECURE Act (21)
Biosimilars (111)
Biotechnology (472)
Bladder cancer (64)
Brain cancer (27)
Breast cancer (267)
Cancer (2129)
Cardiovascular disease (179)
Career advice (2444)
Career pathing (32)
CAR-T (156)
Cell therapy (435)
Cervical cancer (21)
Clinical research (69903)
Collaboration (830)
Compensation (478)
Complete response letters (25)
COVID-19 (2785)
CRISPR (41)
C-suite (227)
Cystic fibrosis (105)
Data (2027)
Decentralized trials (2)
Denatured (21)
Depression (48)
Diabetes (265)
Diagnostics (6809)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (121)
Drug pricing (113)
Drug shortages (30)
Duchenne muscular dystrophy (88)
Earnings (91404)
Editorial (39)
Employer branding (22)
Employer resources (154)
Events (123743)
Executive appointments (690)
FDA (18573)
Featured Employer (57)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (736)
Gene editing (106)
Generative AI (24)
Gene therapy (309)
GLP-1 (783)
Government (4873)
Grass and pollen (5)
Guidances (49)
Healthcare (20710)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (120)
Indications (27)
Infectious disease (2932)
Inflammatory bowel disease (144)
Inflation Reduction Act (10)
Influenza (53)
Intellectual property (90)
Interviews (508)
IPO (17340)
IRA (50)
Job creations (4487)
Job search strategy (2082)
Kidney cancer (10)
Labor market (35)
Layoffs (515)
Leadership (19)
Legal (8827)
Liver cancer (75)
Lung cancer (307)
Lymphoma (136)
Machine learning (4)
Management (63)
Manufacturing (293)
MASH (66)
Medical device (14428)
Medtech (14433)
Mergers & acquisitions (20807)
Metabolic disorders (696)
Multiple sclerosis (77)
NASH (22)
Neurodegenerative disease (97)
Neuropsychiatric disorders (29)
Neuroscience (1984)
NextGen: Class of 2025 (7503)
Non-profit (5052)
Northern California (2500)
Now hiring (38)
Obesity (377)
Opinion (265)
Ovarian cancer (75)
Pain (88)
Pancreatic cancer (79)
Parkinson's disease (144)
Partnered (21)
Patents (218)
Patient recruitment (100)
Peanut (51)
People (62293)
Pharmaceutical (139)
Pharmacy benefit managers (21)
Phase I (21738)
Phase II (30514)
Phase III (22953)
Pipeline (1091)
Podcasts (95)
Policy (136)
Postmarket research (3031)
Preclinical (9491)
Press Release (72)
Prostate cancer (98)
Psychedelics (35)
Radiopharmaceuticals (266)
Rare diseases (394)
Real estate (6906)
Recruiting (68)
Regulatory (24560)
Reports (47)
Research institute (2624)
Resumes & cover letters (468)
Rett syndrome (4)
RNA editing (4)
RSV (44)
Schizophrenia (74)
Series A (128)
Series B (83)
Service/supplier (28)
Sickle cell disease (55)
Southern California (2186)
Special edition (18)
Spinal muscular atrophy (159)
Sponsored (29)
Startups (4015)
State (2)
Stomach cancer (14)
Supply chain (65)
Tariffs (14)
The Weekly (72)
United States (22695)
Vaccines (727)
Venture capitalists (38)
Webinars (12)
Weight loss (266)
Women's health (33)
Worklife (17)
Date
Today (110)
Last 7 days (736)
Last 30 days (2886)
Last 365 days (35763)
2025 (8720)
2024 (37585)
2023 (42331)
2022 (53728)
2021 (58532)
2020 (57492)
2019 (50963)
2018 (38640)
2017 (35113)
2016 (35216)
2015 (41391)
2014 (36413)
2013 (33539)
2012 (33479)
2011 (33922)
2010 (32826)
Location
Africa (963)
Alabama (55)
Alaska (7)
Arizona (247)
Arkansas (14)
Asia (44121)
Australia (7752)
California (5824)
Canada (1914)
China (505)
Colorado (263)
Connecticut (283)
Delaware (138)
Europe (101113)
Florida (851)
Georgia (206)
Hawaii (1)
Idaho (62)
Illinois (561)
India (27)
Indiana (314)
Iowa (10)
Japan (146)
Kansas (106)
Kentucky (27)
Louisiana (11)
Maine (69)
Maryland (901)
Massachusetts (4520)
Michigan (232)
Minnesota (398)
Mississippi (2)
Missouri (87)
Montana (31)
Nebraska (26)
Nevada (58)
New Hampshire (68)
New Jersey (1670)
New Mexico (30)
New York (1666)
North Carolina (1077)
North Dakota (8)
Northern California (2500)
Ohio (207)
Oklahoma (15)
Oregon (47)
Pennsylvania (1298)
Puerto Rico (10)
Rhode Island (29)
South America (1353)
South Carolina (19)
South Dakota (1)
Southern California (2186)
Tennessee (96)
Texas (884)
Utah (175)
Virginia (152)
Washington D.C. (64)
Washington State (562)
West Virginia (3)
Wisconsin (63)
779,594 Results for "new england biolabs inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
New England Biolabs® and Inorevia to partner on novel solutions for the preparation of challenging samples for next generation sequencing
New England Biolabs (NEB ®) and Inorevia announce a collaboration to develop automated workflows to maximize data quality by preparation of sequence-ready libraries from challenging samples using NEBNext® library preparation reagents on Inorevia’s Magelia® automation platform.
June 18, 2024
·
4 min read
Press Releases
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
March 21, 2025
·
3 min read
New England Biolabs® Launches NEBNext® Enzymatic 5hmC-seq Kit, for enzyme-based 5hmC detection at single-base resolution
New England Biolabs (NEB®) today announced the launch of the NEBNext Enzymatic 5hmC-seq Kit (E5hmC-seq™), a novel enzyme-based method for the specific detection of 5hmC sites.
February 13, 2024
·
2 min read
biomodal Files Patent Infringement Lawsuit Against New England Biolabs
July 2, 2024
·
2 min read
Press Releases
BioLab Holdings, Inc. Receives IRB Approval for Trial on Membrane Wrap™
February 13, 2025
·
2 min read
Press Releases
OpenEvidence Achieves $1 Billion Valuation in Sequoia-led Round and Announces Content Partnership with the New England Journal of Medicine
February 19, 2025
·
4 min read
Press Releases
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 5, 2025
·
13 min read
Press Releases
New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer
February 5, 2025
·
10 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
Press Releases
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
February 7, 2025
·
15 min read
1 of 77,960
Next
